You Should Absolutely Not Tweeze Or Wax Your Nose Hair And Here's Why
'The nose is a delicate area with numerous blood vessels and mucous membranes,' said Dr. Don J. Beasley, an Idaho-based board-certified otolaryngologist (also known as an ear, nose and throat specialist). Whether you're DIYing it or getting serviced at a salon, yanking out your nose hairs — especially if it's done improperly or without proper hygiene practices in place — may increase the risk of infection, leading to complications such as folliculitis or nasal cellulitis.
Below, we spoke with experts to learn the risks of nose hair waxing and tweezing, as well as the safer alternatives.
The Importance Of Nose Hairs
You may not have given your nose hairs a second thought (aside from how unpleasant they may be), but the fact is, they're there for a reason.
'The primary role of nose hairs is to trap dust, pollen and other airborne particles in the air so that the air you breathe is partially filtered,' said Dr. Michael Jacobs, a New York-based board-certified dermatologist and associate professor of dermatology at Weill Cornell Medical College. He explained that the hairs act as a physical barrier, preventing these allergens from entering the nasal passages and potentially causing irritation or harm to the respiratory system.
Nose hairs also play a protective role by alerting us to potential dangers, Beasley said. 'When something touches the nostril hairs, such as a small insect or other irritants, it triggers a reflexive sneeze, which is the body's way of expelling the intruder or irritant,' he explained.
Beyond this, nose hairs help to maintain optimal moisture levels in the nasal passages. 'Nose hairs trap moisture from exhaled air, preventing the nasal passages from becoming too dry,' Beasley said. 'This moisture helps to humidify the air we breathe, making it more comfortable for our respiratory system.'
Nose hair waxing can be tempting because it provides longer-lasting results compared to alternative methods like trimming. But completely removing your nose hairs means removing the filtration system that's essential to keeping you healthy and warding off infections like nasal vestibulitis and nasal abscess, said Dr. Nicole Aaronson, a Delaware-based board-certified otolaryngologist. 'While waxing doesn't necessarily weaken the immune system, it does breach the skin barrier by creating openings for bacteria to get into the deeper tissues, thus creating the opportunity for infection,' she said.
Nose hair waxing can also come with some side effects, especially if performed in the hands of an untrained person ― or if you do it yourself, for that matter. For one, Aaronson said that wax that's too hot can burn the nasal mucosa, or the tissue lining the nasal cavity. This removal of the top layer of skin can also create small lesions in the nose and put you at greater risk of infection. Plus, waxing can be an irritating process in general. 'Nose waxing can be an uncomfortable experience, as the delicate nasal passages can be sensitive to the pulling sensation, potentially causing temporary pain, redness and irritation,' Beasley said.
Ingrown hairs may also be an issue with nose hair waxing. 'An ingrown hair occurs after a hair is removed when the new hair that regenerates from the follicle can't break through the skin,' Aaronson explained. 'Because waxing pulls out the hair by the roots, the hair must find its way out through the outer layer of the skin again (unlike other hair removal methods where the hair is left at the skin's surface).'
So, what about partial nose hair waxing (that is, removing only the hair located at the front part of the nose)? Aaronson said to avoid this practice, as it 'carries all of the same risks of nasal vestibulitis, ingrown hairs and burning.' Ultimately, Jacobs warned against nose hair waxing altogether to avoid the risk of inhaling more toxins and particles, irritating the nasal membranes and creating ingrown hairs.
Waxing and partial waxing are already off the table, and you can also add tweezing to the list. Aaronson said to avoid plucking out your nose hairs, noting that she has had to perform incision and drainage of nasal abscesses related to plucking of nasal hairs. 'I would not recommend this method of hair removal for the nose,' she said.
If you find that your nose hairs are reaching lengthy, unsightly heights, you can try carefully trimming them with a clean pair of eyebrow scissors, which are effective for removing straggling hairs that are visibly sitting underneath the nostril. If you're concerned with hurting yourself during this process, opt for angled scissors with rounded tips, as they reduce the risk of accidental nicks and cuts and are strategically shaped to get to those hard-to-reach areas. For trimming hairs deeper inside the nose, opt for an electric trimmer — these are both safe and easy to use, and require minimal effort on your part.
These two methods of nose hair trimming — rounded scissors and electric trimmers — are much safer alternatives to waxing and help prevent the risk of ingrown hairs and irritation.
HuffPost.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance
Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MD Martine Zimmermann, PharmD, joins as Executive Vice President of Regulatory Affairs and Quality Assurance These key leadership appointments underscore Inventiva's commitment to long-term growth and operational excellence, with topline results from NATiV3 on track for the second half of 2026 Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ('Inventiva' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ('MASH'), today announced a leadership transition with the appointment of Jason Campagna, MD, PhD, as President of Research and Development ('R&D') and Chief Medical Officer ('CMO') and Martine Zimmermann, PharmD, as Executive Vice President ('EVP') of Regulatory Affairs and Quality Assurance. Dr. Campagna is joining Inventiva's executive leadership team and brings extensive expertise in the MASH field. He succeeds Pierre Broqua, PhD, co-founder and Chief Scientific Officer, who is transitioning to a consulting role as Scientific Advisor, and Michael Cooreman, MD, departing as CMO of the Company. Dr. Campagna most recently was the CMO at Q32 Bio and prior to that was the MASH Global Program Lead and CMO at Intercept Pharmaceuticals. Dr. Zimmermann is also joining the Company's executive leadership team. She was most recently Senior Vice President, Head of Regulatory Affairs at Ipsen where she successfully led a team that secured regulatory approvals of two liver disease drugs, including Iqirvo®, a dual PPARα/δ agonist, for the treatment of primary biliary cholangitis. Prior to Ipsen, Dr. Zimmermann was Senior Vice President and Head of Global Regulatory Affairs & Quality at Alexion Pharma (also known as AstraZeneca Rare Disease). Frederic Cren, CEO of Inventiva stated: 'Jason and Martine both bring exceptional leadership and experience during this pivotal time for the Company as we plan for the readout of our NATiV3 Phase 3 study next year and lanifibranor's potential regulatory approval and commercialization. Having played an integral part in the creation and building of Inventiva, Pierre will continue to actively support the team in a scientific consulting role. I would also like to express my gratitude to Michael for his scientific leadership and contributions in advancing lanifibranor to this stage and we wish him every success in his future endeavors.' Jason Campagna, MD, PhD, President, R&D and CMO of Inventiva commented: 'Inventiva has built a robust scientific and clinical foundation, and I'm thrilled to join the team at this pivotal moment as we advance lanifibranor toward anticipated regulatory submissions. Having led the design and execution of one of the field's most advanced clinical programs at Intercept—including the first-ever NDA submission in this indication—I've seen firsthand both the scientific complexity and the urgency of bringing effective therapies to patients with MASH. I believe the promising results of the Phase 2b NATIVE trial reflect the thoughtful design of lanifibranor development program—and that's deeply exciting to me. With lanifibranor well on its way in the Phase 3 NATiV3 registrational trial, I look forward to working closely with the exceptional team at Inventiva to deliver on the promise of bringing a novel treatment to patients with MASH.' Martine Zimmermann, PharmD, Executive Vice President of Regulatory Affairs and Quality Assurance of Inventiva said: "I'm excited to take on this leadership role at a time when Inventiva is entering a critical regulatory phase for lanifibranor, a first-in-class pan-PPAR agonist for the treatment of MASH. In my career, I've been closely involved in leading global regulatory strategy and approval of compounds for the treatment of chronic liver diseases, including a PPAR, in a number of geographies, including the US, Europe and Japan. I am now eager to apply that experience to support lanifibranor toward a potential approval." About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). Contacts InventivaPascaline ClercEVP, Strategy and Corporate Affairsmedia@ 202 499 8937 ICR HealthcareMedia relations Alexis Feinberg inventivapr@ +1 203 939 2225 ICR HealthcarePatricia L. BankInvestor relations +1 415 513 1284 Important Notice This press release contains certain 'forward-looking statements' within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, Inventiva's clinical trials, including Inventiva's ongoing NATiV3 Phase 3 clinical trial of lanifibranor in MASH, including related timing and regulatory matters with respect thereto, clinical trial data releases and publications, the information, insights and impacts that may be gathered from clinical trials, the potential therapeutic benefits of Inventiva's product candidates, potential regulatory submissions, approvals and commercialization, the effective start date of Dr. Campagna and Mrs. Zimmerman, the clinical development of and regulatory plans and pathway for lanifibranor, and future activities, expectations, plans, growth and prospects of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, 'believes', 'anticipates', 'expects', 'intends', 'plans', 'seeks', 'estimates', 'may', 'will', 'would', 'could', 'might', 'should', 'designed', 'hopefully', 'target', 'potential', 'possible', 'aim', and 'continue' and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance, or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates due to a number of factors, including that interim data or data from any interim analysis of ongoing clinical trials may not be predictive of future trial results, the recommendation of the DMC may not be indicative of a potential marketing approval, Inventiva cannot provide assurance on the impacts of the Suspected Unexpected Serious Adverse Reaction on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development programs or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern, Inventiva's ability to obtain financing, to enter into potential transactions, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of lanifibranor, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's and its partners' clinical trials may not support Inventiva's and its partners' product candidate claims, Inventiva's expectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require additional holds and/or amendments to Inventiva's clinical trials, Inventiva's expectations with respect to the clinical development plan for lanifibranor for the treatment of MASH may not be realized and may not support the approval of a New Drug Application, Inventiva's ability to identify additional products or product candidates with significant commercial potential, Inventiva's expectations with respect to its pipeline prioritization plan and related workforce reduction, including whether the plan will be implemented and the timing, potential benefits, expenses and consequences relating thereto, Inventiva's ability to execute on its commercialization, marketing and manufacturing capabilities and strategy, Inventiva's ability to successfully cooperate with existing partners or enter into new partnerships, and to fulfill its obligations under any agreements entered into in connection with such partnerships, the benefits of its existing and future partnerships on the clinical development, regulatory approvals and, if approved, commercialization of its product candidates, and the achievement of milestones thereunder and the timing thereof, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's and its partners' control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva's and its partners' business, and pre-clinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by changes in law and regulations, unfavorable conditions in its industry, geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, the conflict in the Middle East and the related risk of a larger conflict, health epidemics, and macroeconomic conditions, including developments in international trade policies, global inflation, financial and credit market fluctuations, tariffs and other trade barriers, political turmoil and natural catastrophes, uncertain financial markets and disruptions in banking systems. The review of potential financial and strategic options may not result in any particular action or transaction being pursued, entered into or consummated, and there is no assurance as to the timing, sequence or outcome of any action or transaction or series of actions or transactions. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Please refer to the Universal Registration Document for the year ended December 31, 2024, filed with the Autorité des Marchés Financiers on April 15, 2025, and the Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (the 'SEC') on April 15, 2025 for other risks and uncertainties affecting Inventiva, including those described under the caption 'Risk Factors' and in future filings with the SEC. Other risks and uncertainties of which Inventiva is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements. Attachment Inventiva - PR - Leadership Team Changes- EN - 07 09 2025Sign in to access your portfolio
Los Angeles Times
an hour ago
- Los Angeles Times
Mattel's newest Barbie has diabetes
Dressed in a matching polka dot tank top and ruffled skirt with blue chunky heeled boots and a mini purse, Mattel's newest Barbie may look like previous dolls at first glance. But this particular doll stands out with a wearable insulin pump on her waist, a glucose monitor on her arm and a phone showing her blood sugar readings, making her the El Segundo-based toy company's first Barbie with Type 1 diabetes. The doll continues Mattel's expansion of representation across its flagship brand. The Barbie Fashionistas line features more than 175 looks across various skin tones, body types and disabilities, including previous additions like a blind Barbie, a Barbie with Down syndrome and a Barbie with hearing aids. The company's commitment to representation has proved commercially successful. In 2024, the top 10 most popular Barbie Fashionista dolls globally included the blind Barbie and the Barbie with Down syndrome. The Fashionistas series also includes dolls with vitiligo, prosthetic limbs and wheelchairs. The wheelchair-using doll has consistently been a top performer since its introduction in 2019. Krista Berger, senior vice president of Barbie and global head of dolls at Mattel, said Barbie helps shape children's early perceptions of the world. Reflecting medical conditions like T1D ensures 'more kids can see themselves in the stories they imagine and the dolls they love.' The doll was developed with Breakthrough T1D, the leading global Type 1 diabetes research and advocacy organization. The partnership ensured medical accuracy while incorporating diabetes awareness symbols through the clothes' blue coloring and polka dot pattern. Aaron J. Kowalski, chief executive of Breakthrough T1D, said the partnership is about 'bringing greater visibility to a condition that affects so many families.' The doll launched Tuesday during Breakthrough T1D's 2025 Children's Congress in Washington, D.C. The event brings together more than 170 children living with Type 1 diabetes, giving them face time with members of Congress to advocate for ongoing funding for Type 1 diabetes research. This year they asked members of Congress to renew funding for the Special Diabetes Program. The Special Diabetes Program's current funding expires after September. The program, first allocated by Congress in 1997, faces uncertainty amid recent cuts to federally-funded projects. Type 1 diabetes is an autoimmune condition affecting nearly 9 million people globally, with about 352,000 children living with diabetes in the United States. The CDC reports that 1.7 million individuals 20 or older live with Type 1 diabetes and use insulin. The new Barbie is available through Mattel Shop and retailers nationwide.
an hour ago
Man bikes across US as father undergoes cancer treatment, fulfilling promises to each other
A Florida man kept a promise to his father by completing a cross-country cycling race as his dad simultaneously underwent treatment for advanced Stage 4 prostate cancer. On Sunday, June 22, Alvaro Nuñez crossed the finish line of the Race Across America, a grueling coast-to-coast 3,000-mile cycling challenge from California to New Jersey that he completed in just under 12 days. Just one month before he set off on the race, Nuñez learned his father had been diagnosed with Stage 4 prostate cancer. What could have been a breaking point became Nuñez's new motivation, the Miami-based entrepreneur told " Good Morning America." Rather than urging Nuñez to be by his side during treatment, Nuñez said his father gave him a new purpose. "He told me, 'Don't you ever, ever say that you're gonna drop on this. You finish what you start. And just so you know, you give me more strength by doing this race than by being here with me,'" Nuñez recalled. "So we made this agreement. And the agreement is that if I didn't quit throughout the race, he wouldn't quit throughout the treatment," he continued. "And when you have a bond, an agreement [that is] so strong, you feel just unstoppable." From that point on, Nuñez said the race became personal. Race Across America isn't for the faint of heart. Spanning 12 days, over 3,000 miles, 12 states, and 150,000 feet of climbing -- approximately five times the height of Mount Everest -- it's widely considered one of the hardest endurance challenges on the planet. And Nuñez had never even raced a bike competitively before. Standing 6 feet, 4 inches and weighing over 200 pounds, he trained obsessively for up to 12 hours a day on the bike, running on minimal sleep. Their strength carried each other During the race, Nuñez said he averaged just one hour of sleep per night. He said he hallucinated, lost feeling in his hands and feet, and at times, he said he could barely eat or think. But he said he kept going for his dad. The two talked throughout the race, checking in as often as they could. Nuñez told "GMA" he later learned that every day before treatment, his dad would rush the doctors, telling them, "Hurry up because my son is about to make it to the time station and to this cutoff time, I need to be there for him." When Nuñez crossed the finish line in Atlantic City, New Jersey, he did so with his dad on FaceTime. "That was one of the most emotional moments ever and one of those moments that I was visualizing throughout the race, of me crossing that finish line and seeing my dad on the other [side]," he recalled. In a statement to "GMA," Rick Boethling, executive director of Race Across America, praised Nuñez's commitment. "When I spoke with Alvaro last year, when he crewed for a 2-person relay team, he said he was going to race solo the next year. I hear that a lot and oftentimes it is just words," Boethling said. "When he registered I was sort of surprised. It is really impressive that he decided to race and then put together a successful rookie race in under a year. Many people take years to prepare." "His dedication to success, not only in his career, but also preparing for RAAM, really shone through. As with every RAAM finisher we are super excited for him," Boethling added. Nuñez said he is still recovering physically and emotionally from the race. Now, as he continues to support his father, Nuñez said he is focused on sharing what he learned about motivation and love. "Pain fades and glory stays," he said. "It's about just staying in the game for as long as you can. And sometimes we are going through a lot of pain and we quit when we are so close to the end … so for those out there that are struggling in their own battles, that are fighting every day, just keep on going."
